--- title: Buy Tenofovir Emtricitabine 300/200mg Tablets Online description: Tenofovir Emtricitabine 300/200mg tablets for HIV treatment and prevention in adults. Shop our secure pharmacy for quality and discreet shipping. type: product language: en url: https://liabilis.com/order-tenofovir-emtricitabine-online-en.html availability: in_stock shipping: - type: Standard Airmail price: 10.00 currency: USD area: Worldwide time: 14-21 days - type: Tracked Express price: 30.00 currency: USD area: Worldwide tracking: true time: 5-9 days price_min: 83.99 price_max: 193.99 currency: USD offers: - name: 300/200mg x 30 tabs price: 83.99 - name: 300/200mg x 60 tabs price: 143.99 - name: 300/200mg x 90 tabs price: 193.99 --- # Buy Tenofovir Emtricitabine 300/200mg Tablets Online Tenofovir Emtricitabine is a combination of two nucleoside reverse transcriptase inhibitors used for HIV-1 treatment or as PrEP to reduce infection risk. It inhibits viral replication in adults. This regimen supports viral suppression or prevention. Available in 300/200mg tablets from our online pharmacy. ## Pricing and Options | Dosage | Pack Size | Price (USD) | Price Per Pill | Status | | :--- | :--- | :--- | :--- | :--- | | **300/200mg** | 30 tabs | **$83.99** | $2.80 | In Stock | | **300/200mg** | 60 tabs | **$143.99** | $2.40 | In Stock | | **300/200mg** | 90 tabs | **$193.99** | $2.16 | In Stock | [Buy Now](https://liabilis.com/order-tenofovir-emtricitabine-online-en.html) ## Introduction Tenofovir Emtricitabine is a fixed-dose oral tablet that combines two nucleoside reverse transcriptase inhibitors (NRTIs): tenofovir disoproxil fumarate and emtricitabine. It belongs to the antiretroviral therapeutic class used to suppress Human Immunodeficiency Virus (HIV) replication. The tablet is available in a single strength of 300 mg tenofovir and 200 mg emtricitabine. In addition to its primary role in HIV treatment, the combination is also approved for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV acquisition in high-risk individuals. ## Quick Reference Facts **Active Ingredient** : Tenofovir/Emtricitabine **Form** : tab 300/200 mg **Primary and Off-Label Uses** : HIV-1 infection (treatment) : Pre-exposure prophylaxis (PrEP) : Hepatitis B virus (HBV) infection - off-label : Post-exposure prophylaxis (PEP) - off-label ## What is Tenofovir Emtricitabine? Tenofovir Emtricitabine is the generic version of medications containing the active compound Tenofovir/Emtricitabine. It is marketed under brand names such as **Truvada** and is produced by multiple licensed manufacturers worldwide. As a generic product, it must demonstrate bioequivalence to the reference brand, meaning it delivers the same amount of active drug into the bloodstream and provides comparable therapeutic outcomes. The tablet is classified as a combination antiretroviral medication. Because it is a generic, patients often experience significant cost savings while receiving a medication that meets the same rigorous FDA or EMA standards as the branded counterpart. ## How Tenofovir Emtricitabine Works Both tenofovir and emtricitabine are analogues of natural nucleosides. After oral absorption, tenofovir is converted to its active diphosphate form, and emtricitabine to its triphosphate form. These active metabolites compete with the natural building blocks of viral DNA during the reverse transcription process. When incorporated into the growing viral DNA chain, they lack a 3′-hydroxyl group, causing premature termination of the chain and preventing the virus from completing replication. The dual-drug combination provides a synergistic blockade of HIV reverse transcriptase, reducing viral load more effectively than either agent alone. Peak plasma concentrations are reached within 1-2 hours, and the drugs have intracellular half-lives of 150 hours (tenofovir) and 40 hours (emtricitabine), allowing once-daily dosing. Both agents are eliminated primarily by the kidneys; tenofovir is secreted via organic anion transporters, whereas emtricitabine is cleared by glomerular filtration and tubular secretion. ## Conditions Treated with Tenofovir Emtricitabine - **HIV-1 infection (treatment)** The combination suppresses viral replication, allowing immune recovery and reducing the risk of opportunistic infections. It is recommended as part of a complete antiretroviral regimen in adults and adolescents. - **Pre-exposure prophylaxis (PrEP)** Daily use in HIV-negative individuals at substantial risk (e.g., men who have sex with men, serodiscordant couples) decreases the incidence of HIV acquisition by up to 99% when adherence is high. - **Post-exposure prophylaxis (PEP) - off-label** When initiated within 72 hours of a potential HIV exposure, the regimen is sometimes incorporated into a 28-day PEP course together with other antiretrovirals. - **Chronic hepatitis B virus (HBV) infection - off-label** Tenofovir possesses activity against HBV; the combination may be used in patients co-infected with HIV/HBV or in HBV monoinfection when other options are limited. Monitoring for viral rebound is essential if therapy is discontinued. ## Is Tenofovir Emtricitabine the Right Medication for You? - **Suitable patients** Individuals diagnosed with HIV who require a nucleoside backbone in their regimen, and HIV-negative persons with documented high-risk exposure for PrEP, are primary candidates. Renal function (creatinine clearance ≥50 mL/min) should be confirmed before initiation. - **Clinical scenarios favoring use** Tenofovir Emtricitabine is preferred when a once-daily, low-pill-burden regimen is desired, especially in patients with co-existing HBV infection, as it provides dual antiviral activity. It is also advantageous for patients who prefer a single-tablet regimen to simplify adherence. - **Contraindications and cautions** The medication should not be used in patients with known hypersensitivity to either component. Severe renal impairment (creatinine clearance <30 mL/min) or active uncontrolled hepatitis B without a plan for continuation may preclude its use. Clinicians should assess bone mineral density in patients at risk for osteoporosis, as tenofovir can affect bone health. ## Buying Tenofovir Emtricitabone from [our online pharmacy](https://liabilis.com/order-tenofovir-emtricitabine-online-en.html) ### Why Choose Our Service? Accessing Tenofovir Emtricitabine can be challenging due to insurance restrictions or regional shortages. Our service offers a reliable pathway to obtain the medication at a price close to the manufacturer’s wholesale cost, helping patients maintain uninterrupted therapy. ### Quality & Safety Assurance We partner with licensed international pharmacies to ensure quality and authenticity. Every shipment is sourced from suppliers that comply with recognized regulatory frameworks such as the FDA’s cGMP standards. ### Pricing & Access Because Tenofovir Emtricitabone is available as a generic, we can provide it at a fraction of the expense of brand-name Truvada. This cost advantage is especially important for long-term treatment or PrEP programs where monthly budgeting matters. ### Discreet Delivery Orders are packaged in plain, unmarked boxes and dispatched via express delivery within 7 days for most destinations, or standard airmail in approximately 3 weeks. Our logistics partners prioritize privacy, ensuring that your medication arrives securely and confidentially. ## Use: Dosing, Missed Dose, Overdose - **Standard dosing** - **Adults**: One tablet (300 mg tenofovir / 200 mg emtricitabine) taken orally once daily, with or without food. - **Renal adjustment**: For creatinine clearance 30-49 mL/min, some guidelines recommend a reduced dose or increased dosing interval; confirm with your clinician. - **Missed dose** - If you miss a dose and it is less than 8 hours late, take it as soon as you remember. - If more than 8 hours have passed, skip the missed dose and resume the regular schedule. Do not take a double dose to “make up” for the missed tablet. - **Overdose** - Symptoms may include nausea, vomiting, abdominal pain, and dizziness. - Seek immediate medical attention or call a poison control center. Supportive care, including gastrointestinal decontamination, may be administered under professional supervision. - **Practical precautions** - Stay well-hydrated to support renal clearance. - Avoid concomitant use of nephrotoxic agents (e.g., non-steroidal anti-inflammatory drugs) unless medically necessary. - Do not operate heavy machinery if you feel dizzy or unwell after dosing. ## Safety Information ### ⚠️ Who Should Not Take Tenofovir Emtricitabone - Patients with documented hypersensitivity to tenofovir, emtricitabine, or any excipients in the tablet. - Individuals with severe renal impairment (creatinine clearance <30 mL/min) unless dose-adjusted under specialist guidance. - Pregnant women should only use the medication when the benefits outweigh potential risks; consult a healthcare provider. ### Common Side Effects - **Nausea and mild gastrointestinal upset** - usually transient, can be mitigated by taking the tablet with food. - **Headache** - often resolves within the first weeks of therapy. - **Fatigue or mild dizziness** - monitor and report persistent symptoms. ### Serious Side Effects (Seek Immediate Medical Help) - **Renal toxicity** - sudden increase in serum creatinine, swelling, or reduced urine output. - **Lactic acidosis** - rapid breathing, abdominal pain, unusual fatigue, or muscle pain. - **Severe hepatitis** - jaundice, dark urine, or elevated liver enzymes. - **Bone demineralization** - new or worsening bone pain, especially in patients with osteoporosis risk factors. ### Drug & Food Interactions - **Antacids containing aluminum or magnesium** - may decrease absorption; separate dosing by at least 2 hours. - **Non-steroidal anti-inflammatory drugs (NSAIDs)** - increase risk of renal impairment; monitor kidney function. - **Protease inhibitors (e.g., atazanavir, lopinavir/ritonavir)** - can raise tenofovir plasma concentrations; dose adjustments may be required. - **Didanosine** - concurrent use raises risk of nephrotoxicity; avoid combination. ## Off-Label and Investigational Uses of Tenofovir Emtricitabone - **Post-exposure prophylaxis (PEP)** - Some clinical protocols incorporate Tenofovir Emtricitabone as part of a 28-day PEP regimen when started promptly after potential HIV exposure. - **HBV monoinfection** - Though tenofovir is approved for HBV, the combination with emtricitabine is sometimes used off-label in regions where the single-agent formulation is unavailable. - **HIV pre-exposure prophylaxis for women using vaginal rings** - Research is evaluating whether Tenofovir Emtricitabone can be delivered effectively via long-acting vaginal devices. All off-label applications should be undertaken only under direct supervision of a qualified healthcare professional, as efficacy and safety have not been formally approved by regulatory agencies for these indications. ## Storage & Handling - Store tablets at **20-25 °C (68-77 °F)**; excursions permitted between **15-30 °C (59-86 °F)**. - Protect from excess moisture and direct sunlight. - Keep the container tightly closed and out of reach of children. - Discard any tablets that are discolored, broken, or past the expiration date. - For safe disposal, follow local pharmacy take-back programs or incinerate according to hazardous waste guidelines. ## Frequently Asked Questions **Practical Use & Lifestyle** - **Can I travel internationally with Tenofovir Emtricitabone?** Yes. Carry the medication in its original packaging with a copy of your prescription or a physician’s letter, as some countries require documentation for antiretrovirals. - **Should I take Tenofovir Emtricitabone with food?** The tablet can be taken with or without meals. Taking it with food may lessen mild stomach upset for some patients. - **How does alcohol affect this medication?** Moderate alcohol intake does not directly interact with Tenofovir Emtricitabone, but excessive drinking can worsen liver function and interfere with adherence. - **Is it safe to use vitamins or supplements while on Tenofovir Emtricitabone?** Most over-the-counter vitamins are compatible, but calcium or multivitamins containing high levels of divalent cations should be taken at least 2 hours apart to avoid absorption interference. **Product & Formulation Details** - **What does the tablet look like?** Generic 300/200 mg tablets are typically white, round, and film-coated, bearing the imprint “300/200” or a manufacturer-specific code. - **Can the tablet be split?** Because the dosage is fixed-dose, splitting is not recommended and may result in uneven drug distribution. - **Are there any inactive ingredients I should be aware of?** Common excipients include lactose, magnesium stearate, and microcrystalline cellulose. Patients with severe lactose intolerance should verify the specific formulation with the supplier. **Regulatory & Safety Nuances** - **Will Tenofovir Emtricitabone appear on a standard drug test?** It is not screened for in routine employment drug panels, as it is not an illicit substance. - **Is Tenofovir Emtricitabone approved for use in people over 65?** The medication is approved for adults of any age, but clinicians should assess renal function more frequently in older patients. - **Can athletes compete while taking Tenofovir Emtricitabone?** Yes, it is not a prohibited substance under major sports anti-doping regulations; however, any adverse health effects should be promptly reported to a team physician. - **What are the import rules for receiving this medication internationally?** Importation for personal use is generally permitted in many jurisdictions when accompanied by a valid prescription; however, local customs regulations vary, so checking national guidelines is advisable. **Scientific & Clinical Curiosity** - **When was Tenofovir Emtricitabone first approved?** The fixed-dose combination received FDA approval for HIV treatment in 2004 and for PrEP in 2012. - **How does Tenofovir Emtricitabone compare to Tenofovir alafenamide (TAF) regimens?** Tenofovir alafenamide delivers lower plasma tenofovir concentrations, reducing renal and bone toxicity, but at a higher cost. Both achieve similar viral suppression when combined with emtricitabine. - **What key clinical trial demonstrated its efficacy for PrEP?** The iPrEx study showed a 44% reduction in HIV acquisition overall, rising to >90% among participants with detectable drug levels, establishing the regimen’s preventive efficacy. ## Glossary **Reverse Transcriptase Inhibitor** : A class of antiretroviral drugs that block the enzyme reverse transcriptase, which HIV uses to convert its RNA into DNA. **Bioequivalence** : The demonstration that a generic drug delivers the same amount of active ingredient into the bloodstream as the reference branded product. **Creatinine Clearance** : A measure of kidney function that estimates how effectively the kidneys filter waste; used to adjust dosing of renally cleared medications. ## Disclaimer The information provided about **Tenofovir Emtricitabone** is intended for general educational purposes and does not replace professional medical consultation. All therapeutic decisions, including those concerning off-label applications, should be undertaken under the guidance of a qualified healthcare provider. Readers are presumed to be responsible adults capable of making informed health choices. Our pharmacy service offers access to **Tenofovir Emtricitabone** for individuals who may encounter limited availability through conventional pharmacies, insurance networks, or who seek cost-effective generic alternatives. Always discuss any medication changes, initiation, or discontinuation with your physician before proceeding.